Meta Biomed Co., Ltd.

KOSDAQ:A059210 Stock Report

Market Cap: ₩93.5b

Meta Biomed Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Meta Biomed.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Medical Equipment earnings growth36.5%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

No updates

Recent updates

Meta Biomed (KOSDAQ:059210) Shareholders Will Want The ROCE Trajectory To Continue

Dec 17
Meta Biomed (KOSDAQ:059210) Shareholders Will Want The ROCE Trajectory To Continue

Earnings Tell The Story For Meta Biomed Co., Ltd. (KOSDAQ:059210) As Its Stock Soars 30%

Feb 26
Earnings Tell The Story For Meta Biomed Co., Ltd. (KOSDAQ:059210) As Its Stock Soars 30%

Here's How We Evaluate Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Dividend

Apr 11
Here's How We Evaluate Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Dividend

Meta Biomed's (KOSDAQ:059210) Stock Price Has Reduced 58% In The Past Five Years

Mar 14
Meta Biomed's (KOSDAQ:059210) Stock Price Has Reduced 58% In The Past Five Years

Are Meta Biomed's (KOSDAQ:059210) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Feb 21
Are Meta Biomed's (KOSDAQ:059210) Statutory Earnings A Good Reflection Of Its Earnings Potential?

Can Meta Biomed (KOSDAQ:059210) Continue To Grow Its Returns On Capital?

Feb 03
Can Meta Biomed (KOSDAQ:059210) Continue To Grow Its Returns On Capital?

Is Meta Biomed (KOSDAQ:059210) A Risky Investment?

Jan 13
Is Meta Biomed (KOSDAQ:059210) A Risky Investment?

Here's Why I Think Meta Biomed (KOSDAQ:059210) Is An Interesting Stock

Dec 26
Here's Why I Think Meta Biomed (KOSDAQ:059210) Is An Interesting Stock

Meta Biomed (KOSDAQ:059210) Share Prices Have Dropped 22% In The Last Five Years

Dec 08
Meta Biomed (KOSDAQ:059210) Share Prices Have Dropped 22% In The Last Five Years

Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

Nov 20
Meta Biomed Co., Ltd.'s (KOSDAQ:059210) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Meta Biomed has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

KOSDAQ:A059210 - Analysts future estimates and past financials data (KRW Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
9/30/202492,30015,1945,84717,912N/A
6/30/202490,09114,7345,93718,952N/A
3/31/202484,43812,3097515,118N/A
12/31/202383,10110,292-1,27710,217N/A
9/30/202379,5456,787-6,2419,632N/A
6/30/202377,7473,141-10,0707,265N/A
3/31/202375,4284,645-1,9645,952N/A
12/31/202268,9421,874-6,1509,159N/A
9/30/202266,8837,1271,07210,295N/A
6/30/202261,3728,6045,79311,763N/A
3/31/202260,7958,8321,93414,655N/A
12/31/202158,7809,3819,03611,136N/A
9/30/202154,1834,4907,3569,437N/A
6/30/202151,8614,1965,6727,628N/A
3/31/202145,793-1,0931,6383,950N/A
12/31/202044,998-3,0911,8104,862N/A
9/30/202046,8232,0352274,486N/A
6/30/202049,0751,980-4,1911,810N/A
3/31/202056,0345,445-5,2911,411N/A
12/31/201959,3915,527-5,2042,865N/A
9/30/201952,268156-5,1222,248N/A
6/30/201953,19264-28,883-20,263N/A
3/31/201951,518-1,435-8,893-1,167N/A
12/31/201852,586953-16,163-5,283N/A
9/30/201864,158-4,131-24,772-8,173N/A
6/30/201865,530-2,666N/A14,076N/A
3/31/201866,563-2,753N/A-3,204N/A
12/31/201765,341-4,104N/A-249N/A
9/30/201766,531262N/A3,853N/A
6/30/201764,329-635N/A6,498N/A
3/31/201764,383761N/A6,642N/A
12/31/201665,784639N/A5,033N/A
9/30/201665,6392,240N/A4,703N/A
6/30/201667,2361,476N/A2,429N/A
3/31/201668,227322N/A2,279N/A
12/31/201568,592806N/A4,933N/A
9/30/201567,332-2,369N/A2,626N/A
6/30/201566,230-3,088N/A964N/A
3/31/201563,748-4,242N/A962N/A
12/31/201461,365-4,952N/A-296N/A
9/30/201458,403-1,117N/A1,496N/A
6/30/201459,885-619N/A3,648N/A
3/31/201463,4231,752N/A4,627N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if A059210's forecast earnings growth is above the savings rate (2.7%).

Earnings vs Market: Insufficient data to determine if A059210's earnings are forecast to grow faster than the KR market

High Growth Earnings: Insufficient data to determine if A059210's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if A059210's revenue is forecast to grow faster than the KR market.

High Growth Revenue: Insufficient data to determine if A059210's revenue is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if A059210's Return on Equity is forecast to be high in 3 years time

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/31 18:57
End of Day Share Price 2025/01/31 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Meta Biomed Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution